RADIOTHERAPY-ACTIVATED THERAPEUTICS
Radiation.
Activation.
New possibilities.
Harnessing radiotherapy to activate anticancer drugs. PolyAdvant brings targeted delivery and radiation-responsive chemistry together to advance precision oncology.
THE POLYADVANT APPROACH
The treatment beam becomes
the drug activation signal.
Our platform explores active-drug release within the irradiated region, connecting the spatial precision of radiotherapy with targeted therapeutic design.
Deliver
Targeted small-molecule or antibody conjugates carry an anticancer payload.
Activate
Ionizing radiation provides an externally controlled chemical signal.
Release
The responsive design aims to release active payload in the treatment field.
OUR PIPELINE
Two modalities.
One activation strategy.
Radiation-responsive chemistry applied across a targeted small-molecule conjugate and an antibody–drug conjugate.
XP-102
GLUT1-targeted radiotherapy-activated conjugate
An investigational program combining tumor-targeted delivery with radiation-responsive payload release.
Explore XP-102 ↗XPADC-106
Radiotherapy-activated ADC
An investigational cetuximab–MMAE conjugate incorporating a radiation-responsive linker.
Explore XPADC-106 ↗FOUNDATIONAL RESEARCH
Nature ChemistryVolume 13 · 2021
Switching on prodrugs using radiotherapy
Peer-reviewed proof of concept for gamma/X-ray-mediated activation of anticancer prodrugs, establishing the scientific foundation for PolyAdvant's platform.
Read the publication ↗PARTNER WITH POLYADVANT